NanoViricides, Inc. NNVC

Company Overview

NanoViricides, Inc. is a U.S.-based biotechnology company focused on developing antiviral therapeutics using nanomedicine-based drug design. The company operates within the biopharmaceutical and antiviral drug development industries and is primarily engaged in creating treatments for viral infections that currently have limited therapeutic options. Its core technology platform is based on proprietary “nanoviricide” constructs designed to mimic human cell surface features targeted by viruses, with the goal of binding to and neutralizing viral particles before they infect cells. The company’s primary revenue activity historically has not come from commercialized products, as it remains a clinical-stage biotechnology company, but rather from research and development activities and capital raising through equity financing.

NanoViricides has concentrated development efforts on therapies targeting viruses such as herpesviruses, influenza, RSV, COVID-19-related coronaviruses, and orthopoxviruses including mpox. A significant strategic focus has been the development of NV-387, a broad-spectrum antiviral candidate evaluated for multiple viral indications. The company was founded in 2005 and evolved from earlier nanotechnology and polymer chemistry research associated with TheraCour Pharma, Inc., which licensed foundational technologies to NanoViricides. Its positioning is differentiated by its attempt to combine targeted antiviral binding mechanisms with nanomaterial-based drug delivery and viral neutralization approaches.